Kura Oncology to Present at the Jefferies 2015 Global Healthcare Conference
A live audio webcast and replay will be available in the Investors section of Kura's corporate website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers. Kura's diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. The company's lead drug candidate is tipifarnib, a farnesyl transferase inhibitor which is currently in a Phase 2 clinical study in patients with locally advanced tumors that carry HRAS mutations. The company's preclinical pipeline includes KO-947, an ERK inhibitor, and a menin-MLL inhibitor program. More information about Kura Oncology may be found at www.kuraoncology.com.
CONTACT: INVESTOR CONTACT:
Robert H. UhlManaging Director Westwicke Partners, LLC(858) 356-5932 email@example.com MEDIA CONTACT: Mark CorbaeVice President Canale Communications619-849-5375 firstname.lastname@example.org